Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

NCT03430895 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Non-Transitional Cell Carcinoma of the Urothelial Tract
Small Cell of the Bladder
Adenocarcinoma of the Bladder
Squamous Cell Carcinoma of the Bladder
Metastatic Bladder Cancer

Interventions

DRUG: durvalumab and tremelimumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]